Pre-earnings options volume in Aquestive Therapeutics (AQST) is normal with calls leading puts 23:1. Implied volatility suggests the market is anticipating a move near 4.2%, or 18c, after results are released. Median move over the past eight quarters is 7.6%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- AQST Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Aquestive Highlights Strategy, Pipeline and Risk Disclosures
- Aquestive announces poster presentations on Anaphylm at AAAAI meeting
- Aquestive Therapeutics: Strengthened Leadership and Regulatory Clarity Underpin Buy Rating on Anaphylm Opportunity
- Aquestive Therapeutics appoints Greenhawt as Chief Medical Officer